Background secondary outcomes comprised ovulation confirmation, pain (Visual Analogue Scale, VAS), and symptom burden (Daily Record of Severity of Problems, DRSP).Results: Baseline demographic and cycle characteristics were comparable between the two groups. By cycle 3, the melatonin group demonstrated significantly higher day 21 progesterone (median 9.85 ng/mL IQR 9.66-13.40 vs. 8.78 6.73–9.81, P<0.0001) and day 24 progesterone (mean±SD 11.15±3.47 ng/mL vs. 9.05±3.14 ng/mL, P=0.0021). A greater proportion exceeded the ≥10 ng/mL threshold on day 21 (32.0% vs. 10.0%, P=0.0141). DRSP luteal mean scores were significantly lower with melatonin (45.14±14.84 vs. 52.16±10.17, P=0.0071), indicating reduced symptom burden. No significant between-group differences were found in VAS pain scores or ≥30% pain reduction rates. Ovulation confirmation rates were similar in the two groups.Conclusion: Circadian-aligned melatonin supplementation significantly improved luteal progesterone profiles and reduced overall luteal-phase symptom severity in women with LPD, without a statistically significant effect on mean pain scores. These findings support melatonin’s potential as a low-risk, non-hormonal adjunct targeting both endocrine and symptomatic dimensions of LPD, meriting further investigation in fertility-focused trials.
Aseel Mosa Jabber (Sun,) studied this question.